Call for Abstract

5th International Conference on Antibiotics, will be organized around the theme “The Antibiotic Resistance Crisis: Causes and Threats”

Antibiotics Summit 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Antibiotics Summit 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

The worldwide fundamental antibiotics showcase was esteemed at $39.6 billion of every 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. The worldwide market for antifungal therapeutics was esteemed at $10.7 billion in 2013 and is anticipated to reach $12.2 billion in 2018, a five-year compound yearly development rate (CAGR) of 2.7%. This calls for uniting at a forum to discuss the present scenario, uptake and consequences associated with antibiotics. This session will witness discussion from global experts on this aspect towards a better efficacy and safe usage of antibiotics.

  • Track 1-1Introduction to antibiotic uses and challenges
  • Track 1-2Basic principles of prescribing antibiotics
  • Track 1-3Mechanisms of bacteriostatic or bactericidal action
  • Track 1-4Mechanism of Action of Antibiotics
  • Track 1-5Randomized Control Trails

This segment manages to bring the most recent medicinal disclosures to the conference. This segment focuses on the targets of acquainting members with real ideas related to the  rising and re-rising infectious diseases, and building up a comprehension of the connection between biomedical research and personal and public health. New diseases are emerging worldwide and old diseases are re-emerging as infectious operators develop or spread, and as changes occur in environment, socioeconomic conditions, and populace designs. In like manner, numerous ailments thought to be sufficiently controlled have all the earmarks of being making a rebound. In developed  nations, public health measures, for example, sanitation, sewage treatment, inoculation projects, and access to great restorative care-including an extensive variety of antibiotics have virtually eliminated “customary" infections, for example, diphtheria, whooping cough, and tuberculosis. The microbial world is complex, dynamic and constantly emerging. Infectious agents reproduce quickly, mature frequently, cross the particular obstruction between humans and animals, and adjust with relative ease to their new surroundings. On account of these characteristics, infectious agents can modify their epidemiology, their virulence, and their susceptibility to anti- infective medications.

  • Track 2-1Resistance and re-emerging theories
  • Track 2-2Medication procedures
  • Track 2-3Molecular mechanism of resistance
  • Track 2-4New drugs for emerging diseases

Fundamental to all good antibiotic (or some other) therapy is diagnosis. In spite of the fact that antibiotics are, in general, safe, they additionally have numerous dangers related with their utilization, including the advancement of unfavorably susceptible responses, Clostridium difficile infection, and antibiotic resistance, and also a higher sticker price. Accordingly, numerous clinicians incline toward endorsing a shorter treatment course. However, it also is important to give a significant treatment course with the goal that so that an infection is treated adequately and relapse is prevented. This session focuses on the general principles for setting optimal antibiotic durations of therapy.


  • Track 3-1Principles of Antibiotic Therapy
  • Track 3-2Groupings of Bacteria for Rational Antibiotic Selection
  • Track 3-3Interaction and Side-effects of Antibiotics
  • Track 3-4The next Gen Approach to Antibiotics

The developing healthcare issue of antimicrobial resistance essentially affected people in general welfare and has significantly loaded the financial framework on a worldwide scale. With an end goal to battle this rising issue, a few procedures have been executed in the current years to slow down the movement and diminishing the development of antimicrobial resistance. The aim of this conference is to portray the different variables that have added to the present condition of antimicrobial resistance and to assess potential procedures created to decrease the weight of antimicrobial resistance.

The US Centers for Disease Control and Prevention (CDC) reported that anti-toxin safe pathogens sicken 2 million Americans every year and recorded the three most pressing dangers as Clostridium difficile, carbapenem-safe Enterobacteriaceae (CRE), and Neisseria gonorrhoeae. Anti-toxin safe microorganisms assume a part in 23,000 deaths every year, the CDC reported.

In 2009, the ECDC and The European Medicines Agency (EMA) evaluated that the general cost for the EU in terms of additional human expenses and profitability misfortunes totaled at least EUR 1.5 billion every year. For the US, gauges are as high as $20 billion in abundance coordinate medicinal services costs, with extra expenses to society for lost efficiency as high as $35 billion a year. Studies on deaths infer-able from a little and varying determination of MDR infections demonstrate that, every year, these infections result in an expected 25000 deaths in 29 nations in Europe (5.1 for each 100 000 tenants) and 23000 deaths in the US.


  • Track 4-1Bacterial antibiotic resistance
  • Track 4-2Novel antibacterial drug discovery
  • Track 4-3Public approach to antimicrobial resistance
  • Track 4-4Proteomics of antimicrobial resistance
  • Track 4-5Genetics of antimicrobial resistance
  • Track 4-6Mechanism of antimicrobial resistance
  • Track 4-7Alternate strategy to overcome the problem of antimicrobial resistance worldwide
  • Track 4-8Preventing drug resistance

Antibiotics changed the world. General deals in the present antibiotics and new products advertise were about $40 billion in 2010. It expanded to $41.5 billion in 2013. By 2019, it is anticipated to increase to $67.5 billion, for a 5-year compound annual growth rate (CAGR) of over 9.6%. The biggest section antibiotic drugs showcase was about $38 billion in 2014; this further expanded to $37 billion in 2016, this anticipated to reach $53 billion in 2017, for a 5-year CAGR of 5.9%. Deals in the bacterial vaccines advertise added up to $3.6 billion in 2010 which expanded slightly to $4.5 billion in 2012. This is anticipated to increase to $15 billion of in 2018, for a 5-year CAGR of 31.6%.


  • Track 5-1Grand challenges – antimicrobial resistance
  • Track 5-2Antibiotics and alternatives
  • Track 5-3Systemic intervention – values, conflict and blue room resolution
  • Track 5-4Intervention against antimicrobial resistance – approaches and implementation

Nowadays, drug delivery organizations are occupied with the advancement of different stage innovations to get competitive advantage, broaden patent life, and increase market share of their products. Once a compound has demonstrated its incentive in these tests, it will start the procedure of drug development preceding clinical trials

This segment concentrates on current well tested procedures of determination of compounds from natural and non-natural sources and altering existing classes. In the past most medications have been found either by distinguishing the key element from conventional cures or by uncertain discovery. Another approach has been to perceive how disease and contamination are controlled at the sub-atomic and physiological level and to target specific substances in light of this data.


  • Track 6-1Policies to stimulate drug development and discovery
  • Track 6-2Role of computational biology
  • Track 6-3Ligand binding studies
  • Track 6-4Simulation studies (transport)
  • Track 6-5Molecule mediating transport

Environmental microorganisms are a major source of drug discovery, and several microbial products (antibiotics, anti-tumor items, immunosuppressants and others) are utilized routinely for human treatments. The greater part of these items were acquired from cultivable (<1%) natural organisms, and this implies that the vast majority of microbes were not targeted for drug discovery. With the approach of new and rising innovations, we are ready to gather novel medications from the alleged "uncultivable" microorganisms. In this session, we propose how a multidisciplinary approach consolidating distinctive innovations can facilitate and examine medication disclosure from uncultivable microorganisms and inspect the present limitations of advances and strategies to defeat such confinements that may additionally extend the guarantee of medications from environmental microbes.

  • Track 7-1Novel species discovery
  • Track 7-2Microbes from different areas (patients, geographical locations)
  • Track 7-3Genetically modified organisms

The antibiotics market generated sales of US$42 billion in 2009 all inclusive, representing 46% of sales of anti-infective agents (which additionally incorporate antiviral medications and vaccines) and 5% of the worldwide pharmaceutical market. However, the antibiotics market is maturing; it demonstrated a normal yearly development of 4% in the course of recent years, contrasted and a development of 16.7% and of 16.4% for antiviral medications and vaccines, individually.

The cephalosporin class of antibiotics is the biggest in terms of sells, producing $11.9 billion in 2009, drove by sales the latest generation of medications in this class (cefcapene (Flomox; Shionogi), ceftriaxone (Rocephin; Roche) and cefuroxime (Zinnat; GlaxoSmithKline).

This class represents 28% of the aggregate antibiotic market, and sales demonstrated a development of 3.4% in the course of recent years. With sales of $7.9 billion and 19% of the antibiotic market share in 2010, the second largest medication class is the broad-spectrum penicillins, which demonstrated a development of 5% in the vicinity of 2005 and 2012. The third biggest medication class — the fluoroquinolones — had sales of $7.1 billion in 2013, representing 17% of the antibiotic market in 2013. By contrast, as  as generic versions of an increasing number of macrolides — which had $4.8 billion in sales in 2012 — became available, sales of this class declined by 5% between 2012 and 2014. Overall, the rate of patent expiry of driving antibiotics in the market is set to increase, with a few of the present top selling items confronting patent expiry in the vicinity of 2010 and 2016. These include levofloxacin (Levaquin; Johnson and Johnson), moxifloxacin (Avelox; Bayer/Merck) and linezolid (Zyvox; Pfizer), which are relied upon to lose patent insurance in 2011, 2014 and 2016, respectively.


  • Track 8-1Hypocholesterolemic agents
  • Track 8-2Lipopeptide
  • Track 8-3Macrolides
  • Track 8-4Monobactams
  • Track 8-5Nitrofurans
  • Track 8-6Oxazolidinones
  • Track 8-7Polypeptides
  • Track 8-8Quinolones
  • Track 8-9Sulfonamides
  • Track 8-10Tetracyclines
  • Track 8-11Lincosamides
  • Track 8-12Glycopeptides
  • Track 8-13Immunosuppressive agents
  • Track 8-14Anti-migraine agents
  • Track 8-15Anti-bacterials
  • Track 8-16Antifungals
  • Track 8-17Penicillins
  • Track 8-18Aminoglycosides
  • Track 8-19Ansamycins
  • Track 8-20Carbapenems
  • Track 8-21Cephalosporins (1,2, 3, 4, 5 generations)
  • Track 8-22Fluoroquinolones

In spite of the fact that the field of antibiotics is growing rapidly as to render it almost kaleidoscopic, amid late months a few points of general intrigue have come into sharp core interest. The subject of first thought will incorporate new medications as well as new types of old medications, and also old medications. Past this, the segment will focus on to two fundamental items, bacterial resistance to antibiotics, and antibiotic toxicity. A variety of biological solutions yet have to be completely investigated.       


  • Track 9-1Empiric Antibiotic Therapy
  • Track 9-2Bacterial Biofilms
  • Track 9-3Intra-Adhesive Antibiotics
  • Track 9-4Oral Antibiotic Therapy
  • Track 9-5Immunomodulation

Antibiotics are important in Human Medicine. But there is an increasing prevalence of antimicrobial resistance and that this resistance has clinical implications, therefore a need for mitigation efforts, including awareness on the intake of food and drugs containing antimicrobial agents. Therapeutic  anticancer antibiotics have turned into an acknowledged treatment for specific types of cancer. These medications binds particularly to primary and metastatic cancer cells to to block cell growth, while constraining consequences for encompassing sound cells. Also called antitumor antibiotics, anticancer antibiotics can likewise be utilized to treat or  prevent infections expedited by malignancy treatments. Antibiotics are generally recommended amid pregnancy. Antibiotics for the most part thought to be safe amid pregnancy: Amoxicillin, Ampicillin, Clindamycin, Erythromycin, Penicillin, Nitrofurantoin. Antibiotics are intended to execute the bacteria that cause infections. Yet, the medications additionally kill off a portion of the ‘good’ bacteria in the gut, which are known to impact absorption and digestion. In this segment we will explore whether utilization of antibiotics impacts the dangers of creating type 2 diabetes and whether the impact can be ascribed to particular types of antibiotics.


  • Track 10-1Antibiotics: In Pregnancy and Lactation
  • Track 10-2Antibiotics for Cancer
  • Track 10-3Antibiotics for Diabetes

Antimicrobial prophylaxis is usually utilized by clinicians for the counteractive action of various infectious diseases. Ideal antimicrobial operators for prophylaxis ought to be bactericidal, nontoxic, reasonable, and dynamic against the typical pathogens that can cause surgical site contamination postoperatively. To expand its adequacy, intravenous perioperative prophylaxis ought to be regulated inside 30 to 60 minutes prior to the surgical cut. Antimicrobial prophylaxis ought to be of brief term to diminish toxicity and antimicrobial resistance and to decrease the cost. Appropriately directed antibiotic prophylaxis reduces the rate of surgical wound infection. This segment talks about the advantage of taking preprocedure antibiotics, who should take antibiotics, and gives a clarification of when antibiotics are normally suggested.


  • Track 11-1Prevention of microbial infection
  • Track 11-2Antibiotic selection
  • Track 11-3Advantages of long-acting antibiotics

It is assessed that more than one-portion of the antibiotics in the U.S. are utilized used in food animal production.  Antibiotics are utilized in food animals to treat clinical illness, to prevent and control common disease events, and to improve animal growth. The utilization of antibiotics in agriculture is routinely portrayed as a noteworthy contributor of the clinical problem of resistant disease in human medicine. The U.S. Food and Drug Administration (FDA) is implementing another system to support more fitting and reasonable utilization of antibiotics in food animal production. The system expects to control antibiotic abuse and overuse by identifying certain antibiotics that will now require veterinary oversight by means of the Veterinary Feed Directive (VFD). The FDA will also help drug companies voluntarily re-label antibiotic products to remove feed efficiency and development advancement claims. Labels will instead emphasize antibiotic use for the prevention, control, and treatment of bacterial infections.


  • Track 12-1Antibiotics in food Industry
  • Track 12-2Antibiotics in agriculture
  • Track 12-3Antibiotics in aquaculture
  • Track 12-4Antibiotics of Veterinary Importance

The improvement of new antibiotics is urgent to controlling current and future infectious diseases caused by antibiotic resistant bacteria. Increased advancement costs, the trouble in recognizing new medication classes, unanticipated medication toxicities, the simplicity by which bacteria create imperviousness to new antibiotic agents and the disappointment of numerous operators to address antibiotic resistance particularly. An expected 5– 10% of all hospitalizations are entangled by a nosocomial disease with an expected cost of $4.5– 5.7 billion every year in the USA alone. 15 HAIs likewise have a tendency to have more prominent mortality than CA infections.16 Some antibiotics can be taken orally, while others are managed by infusion or connected topically to the skin.17  Antibiotics are not powerful against infections and ought to never be taken on account of suspected viral contaminations, for example, normal colds. Utilized legitimately, antibiotics can save lives.


  • Track 13-1Animal Venoms as Natural Sources of Antimicrobials
  • Track 13-2Molecular Epidemiology
  • Track 13-3Experimental Parasitology
  • Track 13-4Validation of new drug targets
  • Track 13-5Zika Virus
  • Track 13-6Non-Randomized Ebola Trails
  • Track 13-7Combination Therapy
  • Track 13-8Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

The worldwide foundational antibiotics market was esteemed at $39.6 billion in 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. Since, 2005 this market apparently grows at a yearly rate of 6.6% until 2011. There are many organizations manufacturing antibiotics nowadays and there are numerous different antibiotics present in the market, for example, aminoglycoside antibiotics and it covers around 79% of the worldwide demand. In addition, alternate antibiotics, for example, penicillin have 8%, tetracyclines 4%, erythromycin 7%, streptomycin 1% and chloramnphenicol has 1 % market.


  • Track 14-1Global antibiotics market
  • Track 14-2Antibiotics market USA
  • Track 14-3Antibiotics market UK